Matches in Wikidata for { <http://www.wikidata.org/entity/Q83785239> ?p ?o ?g. }
Showing items 1 to 53 of
53
with 100 items per page.
- Q83785239 description "artikull shkencor i botuar më 01 janar 2012" @default.
- Q83785239 description "artículu científicu espublizáu en xineru de 2012" @default.
- Q83785239 description "im Jahr 2012 veröffentlichter wissenschaftlicher Artikel" @default.
- Q83785239 description "scientific article published on 01 January 2012" @default.
- Q83785239 description "wetenschappelijk artikel" @default.
- Q83785239 description "наукова стаття, опублікована в січні 2012" @default.
- Q83785239 description "научна статия" @default.
- Q83785239 name "Feasibility of structural modification of retinoid X receptor agonists to separate blood glucose-lowering action from adverse effects: studies in KKA(y) type 2 diabetes model mice" @default.
- Q83785239 name "Feasibility of structural modification of retinoid X receptor agonists to separate blood glucose-lowering action from adverse effects: studies in KKA(y) type 2 diabetes model mice" @default.
- Q83785239 name "Feasibility of structural modification of retinoid X receptor agonists to separate blood glucose-lowering action from adverse effects: studies in KKA(y) type 2 diabetes model mice" @default.
- Q83785239 type Item @default.
- Q83785239 label "Feasibility of structural modification of retinoid X receptor agonists to separate blood glucose-lowering action from adverse effects: studies in KKA(y) type 2 diabetes model mice" @default.
- Q83785239 label "Feasibility of structural modification of retinoid X receptor agonists to separate blood glucose-lowering action from adverse effects: studies in KKA(y) type 2 diabetes model mice" @default.
- Q83785239 label "Feasibility of structural modification of retinoid X receptor agonists to separate blood glucose-lowering action from adverse effects: studies in KKA(y) type 2 diabetes model mice" @default.
- Q83785239 prefLabel "Feasibility of structural modification of retinoid X receptor agonists to separate blood glucose-lowering action from adverse effects: studies in KKA(y) type 2 diabetes model mice" @default.
- Q83785239 prefLabel "Feasibility of structural modification of retinoid X receptor agonists to separate blood glucose-lowering action from adverse effects: studies in KKA(y) type 2 diabetes model mice" @default.
- Q83785239 prefLabel "Feasibility of structural modification of retinoid X receptor agonists to separate blood glucose-lowering action from adverse effects: studies in KKA(y) type 2 diabetes model mice" @default.
- Q83785239 P1433 Q83785239-4BFABCA9-080E-460B-82B8-2FE911ECD6C2 @default.
- Q83785239 P1476 Q83785239-6BDB55CF-2B58-43D3-B82B-4267384B9B4A @default.
- Q83785239 P2093 Q83785239-0CEC8449-0A2B-4091-803F-66616156C88E @default.
- Q83785239 P2093 Q83785239-6A7C028D-458E-49C5-8109-7B849409922F @default.
- Q83785239 P2093 Q83785239-8609DF9E-E073-4B1A-A84E-C314A42982AF @default.
- Q83785239 P2093 Q83785239-BF0AE9EF-894D-42CE-B685-997A29373594 @default.
- Q83785239 P304 Q83785239-FD63E98F-5097-4BD3-8784-6F91C8964AB0 @default.
- Q83785239 P31 Q83785239-5A51C874-72DD-41D3-ACB6-CC86D3771012 @default.
- Q83785239 P356 Q83785239-4264FF46-3394-4B33-B520-216E1DC6845D @default.
- Q83785239 P433 Q83785239-3470AB8B-2D74-4921-8BD9-C162542D3B7A @default.
- Q83785239 P478 Q83785239-F850CA81-CB04-4422-A69D-96B2F610298A @default.
- Q83785239 P50 Q83785239-6C807BAE-07FE-4BD8-A76D-712D2BDC02FF @default.
- Q83785239 P50 Q83785239-83F21342-E7D1-4AF7-88C4-A81D491C09AD @default.
- Q83785239 P50 Q83785239-A8F4E9B8-B0E0-4903-A287-DF056D522B07 @default.
- Q83785239 P577 Q83785239-0115C2DD-EE2C-4988-9A94-94DEF3A8781B @default.
- Q83785239 P698 Q83785239-1F690601-7306-4AB0-8A5B-067304EA816F @default.
- Q83785239 P921 Q83785239-2C0B42D0-15FE-4CAB-B5A5-CF973AA13F52 @default.
- Q83785239 P356 BPB.35.629 @default.
- Q83785239 P698 22466572 @default.
- Q83785239 P1433 Q15754240 @default.
- Q83785239 P1476 "Feasibility of structural modification of retinoid X receptor agonists to separate blood glucose-lowering action from adverse effects: studies in KKA(y) type 2 diabetes model mice" @default.
- Q83785239 P2093 "Akihiro Tai" @default.
- Q83785239 P2093 "Fuminori Ohsawa" @default.
- Q83785239 P2093 "Makoto Makishima" @default.
- Q83785239 P2093 "Shoya Yamada" @default.
- Q83785239 P304 "629-633" @default.
- Q83785239 P31 Q13442814 @default.
- Q83785239 P356 "10.1248/BPB.35.629" @default.
- Q83785239 P433 "4" @default.
- Q83785239 P478 "35" @default.
- Q83785239 P50 Q42821012 @default.
- Q83785239 P50 Q58577709 @default.
- Q83785239 P50 Q61136414 @default.
- Q83785239 P577 "2012-01-01T00:00:00Z" @default.
- Q83785239 P698 "22466572" @default.
- Q83785239 P921 Q3025883 @default.